[1] |
Cox E, Laessig K. FDA approval of bedaquiline-the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med, 2014, 371(8):689-691. doi: 10.1056/NEJMp1314385.
doi: 10.1056/NEJMp1314385
URL
|
[2] |
World Health Organization. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). Geneva: World Health Organization, 2018.
|
[3] |
Somoskovi A, Bruderer V, Hömke R, et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J, 2015, 45(2):554-557. doi: 10.1183/09031936.00142914.
doi: 10.1183/09031936.00142914
pmid: 25359333
|
[4] |
Veziris N, Bernard C, Guglielmetti L, et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons not to repeat past errors. Eur Respir J, 2017, 49(3):1601719. doi: 10.1183/13993003.01719-2016.
doi: 10.1183/13993003.01719-2016
URL
|
[5] |
Andries K, Villellas C, Coeck N, et al. Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline. PLoS One, 2014, 9(7):e102135. doi: 10.1371/journal.pone.0102135.
doi: 10.1371/journal.pone.0102135
URL
|
[6] |
Xu J, Wang B, Hu M, et al. Primary Clofazimine and Beda-quiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother, 2017, 61(6):e00239-17. doi: 10.1128/AAC.00239-17.
doi: 10.1128/AAC.00239-17
|
[7] |
Briffotaux J, Huang W, Wang X, et al. MmpS5/MmpL5 as an efflux pump in Mycobacterium species. Tuberculosis (Edinb), 2017, 107:13-19. doi: 10.1016/j.tube.2017.08.001.
doi: 10.1016/j.tube.2017.08.001
URL
|
[8] |
Xu J, Tasneen R, Peloquin CA, et al. Verapamil increases the bioavailability and efficacy of bedaquiline but not clofazimine in a murine model of tuberculosis. Antimicrob Agents Chemother, 2017, 62(1):e01692-17. doi: 10.1128/AAC.01692-17.
doi: 10.1128/AAC.01692-17
|
[9] |
Xu J, Wang B, Fu L, et al. In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2019, 63(5):e02155-18. doi: 10.1128/AAC.02155-18.
doi: 10.1128/AAC.02155-18
|
[10] |
Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2014, 58(5):2979-2981. doi: 10.1128/AAC.00037-14.
doi: 10.1128/AAC.00037-14
pmid: 24590481
|
[11] |
Sandhu P, Akhter Y. Siderophore transport by MmpL5-MmpS5 protein complex in Mycobacterium tuberculosis. J Inorg Biochem, 2017, 170:75-84. doi: 10.1016/j.jinorgbio.2017.02.013.
doi: 10.1016/j.jinorgbio.2017.02.013
URL
|
[12] |
Sandhu P, Akhter Y. The internal gene duplication and interrupted coding sequences in the MmpL genes of Mycobacterium tuberculosis: Towards understanding the multidrug transport in an evolutionary perspective. Int J Med Microbiol, 2015, 305(3):413-423. doi: 10.1016/j.ijmm.2015.03.005.
doi: 10.1016/j.ijmm.2015.03.005
URL
|
[13] |
Radhakrishnan A, Kumar N, Wright CC, et al. Crystal structure of the transcriptional regulator Rv0678 of Mycobacterium tuberculosis. J Biol Chem, 2014, 289(23):16526-16540. doi: 10.1074/jbc.M113.538959.
doi: 10.1074/jbc.M113.538959
pmid: 24737322
|
[14] |
Daugelat S, Kowall J, Mattow J, et al. The RD1 proteins of Mycobacterium tuberculosis: expression in Mycobacterium smegmatis and biochemical characterization. Microbes Infect, 2003, 5(12):1082-1095. doi: 10.1016/S1286-4579(03)00205-3.
doi: 10.1016/S1286-4579(03)00205-3
pmid: 14554249
|
[15] |
Zhang B, Li J, Yang X, et al. Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target. Cell, 2019, 176(3):636-648. doi: 10.1016/j.cell.2019.01.003.
doi: S0092-8674(19)30036-4
pmid: 30682372
|
[16] |
Yamamoto K, Nakata N, Mukai T, et al. Coexpression of MmpS5 and MmpL5 Contributes to Both Efflux Transporter MmpL5 Trimerization and Drug Resistance in Mycobacterium tuberculosis. mSphere, 2021, 6(1):e00518-20. doi: 10.1128/mSphere.00518-20.
doi: 10.1128/mSphere.00518-20
|
[17] |
Demitto F, Amaral R, Maltempe FG, et al. In vitro activity of rifampicin and verapamil combination in multidrug-resistant Mycobacterium tuberculosis. PLoS One, 2015, 10(2):e0116545. doi: 10.1371/journal.pone.0116545.
doi: 10.1371/journal.pone.0116545
URL
|